Detalhe da pesquisa
1.
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Haematologica
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634143
2.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1): 43-69, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394770
3.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
4.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
5.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
6.
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 108(3): 705-716, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226495
7.
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Am J Hematol
; 98(8): 1254-1264, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37334852
8.
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Value Health
; 26(12): 1689-1696, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37741447
9.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Jpn J Clin Oncol
; 52(1): 29-38, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739075
10.
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.
J Oncol Pharm Pract
; 28(4): 892-897, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191732
11.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood
; 133(1): 7-17, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30361262
12.
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Am J Hematol
; 96(2): 208-217, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119898
13.
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 26(2): 300-306, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31550496
14.
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(10): 1385-1415, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33022644
15.
How I treat FLT3-mutated AML.
Blood
; 129(5): 565-571, 2017 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27872057
16.
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(6): 721-749, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200351
17.
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Am J Hematol
; 94(1): 111-117, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30370956
18.
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Lancet Oncol
; 19(2): 216-228, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29339097
19.
Azacitidine and Venetoclax in AML. Reply.
N Engl J Med
; 383(21): 2088-2089, 2020 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207106
20.
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
Blood
; 127(22): 2711-22, 2016 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26917778